BMS-690514
BMS-690514 is a pharmaceutical drug with 6 clinical trials. Historical success rate of 100.0%.
Success Metrics
Based on 6 completed trials
Phase Distribution
Phase Distribution
3
Early Stage
3
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
100.0%
6 of 6 finished
0.0%
0 ended early
0
trials recruiting
6
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response
A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors
Clinical Trials (6)
A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin
A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response
A Phase I Study of BMS-690514 in Patients With Advanced or Metastatic Solid Tumors
Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors
All 6 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 6